Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 7-Day Trial for You or Your Team.

Learn More →

Additional Support for Consolidative Radiotherapy for Diffuse Large B Cell Lymphoma in the Modern Rituximab Era

Additional Support for Consolidative Radiotherapy for Diffuse Large B Cell Lymphoma in the Modern... In this issue of Acta Haematologica, Hu et al. [1] present a systematic review and meta-analysis of recently published series comparing the role of 6-8 cycles of R-CHOP chemotherapy with or without the addition of consolidative radiotherapy for patients with diffuse large B cell lymphoma, stages I-IV. The authors queried MEDLINE, EMBASE and the Cochrane Library databases. In addition, they also searched abstracts from ASCO, ASTRO, ASH, ECCO and ESMO from 2000 to 2013 and had a relatively stringent and appropriately defined selection and inclusion criteria. This methodology and statistical approach was appropriate and the authors also utilized internal controls with three different investigators reviewing each relevant study, with a 4th reviewer set aside to resolve any disagreements. These techniques helped to reduce bias in the identification and interpretation of studies included in the narrative review and meta-analysis.The authors initially identified 722 papers, of which only 4 studies met the prespecified stringent selection criteria. In their meta-analysis of 633 patients from these studies, the authors concluded that the addition of radiotherapy after complete response to R-CHOP statistically significantly improved overall survival (OS; hazard ratio = 0.33) and progression-free survival/event-free survival (hazard ratio = 0.24). Furthermore, in the subset of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Acta Haematologica Karger

Additional Support for Consolidative Radiotherapy for Diffuse Large B Cell Lymphoma in the Modern Rituximab Era

Download PDF
2 pages

Loading next page...
 
/lp/karger/additional-support-for-consolidative-radiotherapy-for-diffuse-large-b-xnpuGJi8bS

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Karger
Copyright
© 2015 S. Karger AG, Basel
ISSN
0001-5792
eISSN
1421-9662
DOI
10.1159/000371868
Publisher site
See Article on Publisher Site

Abstract

In this issue of Acta Haematologica, Hu et al. [1] present a systematic review and meta-analysis of recently published series comparing the role of 6-8 cycles of R-CHOP chemotherapy with or without the addition of consolidative radiotherapy for patients with diffuse large B cell lymphoma, stages I-IV. The authors queried MEDLINE, EMBASE and the Cochrane Library databases. In addition, they also searched abstracts from ASCO, ASTRO, ASH, ECCO and ESMO from 2000 to 2013 and had a relatively stringent and appropriately defined selection and inclusion criteria. This methodology and statistical approach was appropriate and the authors also utilized internal controls with three different investigators reviewing each relevant study, with a 4th reviewer set aside to resolve any disagreements. These techniques helped to reduce bias in the identification and interpretation of studies included in the narrative review and meta-analysis.The authors initially identified 722 papers, of which only 4 studies met the prespecified stringent selection criteria. In their meta-analysis of 633 patients from these studies, the authors concluded that the addition of radiotherapy after complete response to R-CHOP statistically significantly improved overall survival (OS; hazard ratio = 0.33) and progression-free survival/event-free survival (hazard ratio = 0.24). Furthermore, in the subset of

Journal

Acta Haematologica – Karger

Published: Jan 1, 2015

Keywords: B-cell lymphoma; Immunotherapy; Lymphoma; Radiotherapy; Rituximab

There are no references for this article.